GemVax
Financials
Valuation Metrics
GemVax's Market Cap is ₩5388B. At end of 2025 it was ₩1.3T. Ranked #436 of 2,436 in KR market (top 18%), #151 of 1,649 on KOSDAQ (top 9%), #47 of 214 in Semiconductors & Semiconductor Equipment (top 22%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 538.76B KRW | KR#436/2,436 Sec#47/214 |
| Revenue | 87.41B KRW | KR#1,482/2,436 Sec#121/214 |
| Net Income | -3.94B KRW | KR—/2,436 Sec—/214 |
| Total Assets | 176.23B KRW | KR#1,363/2,436 Sec#117/214 |
| Net Assets | 57.23B KRW | KR#1,781/2,436 Sec#156/214 |
| Employees | 199 | KR#1,104/2,436 Sec#101/214 |
| Value | ||
| P/B | 9.41x | KR#2,338/2,436 Sec#205/214 |
| P/S | 6.16x | KR#2,184/2,436 Sec#183/214 |
| EV/EBITDA | 101.23x | KR#1,465/2,436 Sec#116/214 |
| FCF Yield | 0.02% | KR#1,218/2,436 Sec#101/214 |
| Profitability | ||
| ROE | -6.89% | KR#1,805/2,436 Sec#152/214 |
| ROA | -2.24% | KR#1,721/2,436 Sec#143/214 |
| Op. Margin | 6.85% | KR#721/2,436 Sec#79/214 |
| Revenue Growth | 47.56% | KR#315/2,436 Sec#56/214 |
| Financial Health | ||
| Debt Ratio | 166.88% | KR#1,399/2,436 Sec#132/214 |
| Total Debt | 90.93B KRW | KR#748/2,436 Sec#47/214 |
| FCF | 111.3M KRW | KR#1,215/2,436 Sec#100/214 |
| Cash | 23.96B KRW | KR#1,131/2,436 Sec#102/214 |
| Current Ratio | 1.18x | KR#1,610/2,436 Sec#160/214 |
| Net Debt/EBITDA | 11.19x | KR#1,299/2,436 Sec#116/214 |
| Performance | ||
| 1Y Return | -78.19% | KR#2,396/2,436 Sec#214/214 |
| 1M Return | 6.75% | KR#389/2,436 Sec#21/214 |
| From 52W High | -80.05% | KR#2,349/2,436 Sec#211/214 |
| 1Y MDD | -84.50% | KR#2,362/2,436 Sec#211/214 |
| Trading | ||
| Volume | 274,716 shares | KR#433/2,436 Sec#52/214 |
| Foreign Own. | 7.72% | KR#569/2,436 Sec#62/214 |
| Per Share | ||
| EPS | -93 KRW | KR—/2,436 Sec—/214 |
| BPS | 1,837 KRW | KR#2,077/2,436 Sec#187/214 |
Company Info
GemVax, established in 1998 for the manufacturing and sale of Coating Resin and filters, was listed on the KOSDAQ market in 2005. In its environmental pollution control division, the company specializes in localizing Chemical Filters for semiconductor and display applications, as well as providing air pollution prevention equipment. The bio division conducts clinical trials for diseases such as Alzheimer's using GV1001, simultaneously focusing on expanding overseas demand and researching next-generation peptide drugs. GemVax is headquartered in Seongnam City, Gyeonggi-do.